Jens Fritsche

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

Mahesh Yadav, Suchit Jhunjhunwala, Qui Phung et al. · Nature · 2014 · 1.2K citations

Tumor Biology, Functional Genomics, Immunogenic Tumour Mutations +14

Actively personalized vaccination trial for newly diagnosed glioblastoma

Norbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel et al. · Nature · 2018 · 897 citations

Vaccination, Neuro-oncology, Vaccination Trial +6

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

Steffen Walter, Toni Weinschenk, Arnulf Stenzl et al. · Nature Medicine · 2012 · 777 citations · Full text

Vaccination, Cancer Immunosurveillance, Multipeptide Immune Response +12

Nogo-A and Myelin-Associated Glycoprotein Mediate Neurite Growth Inhibition by Antagonistic Regulation of RhoA and Rac1

Barbara Niederöst, Thomas Oertle, Jens Fritsche et al. · Journal of Neuroscience · 2002 · 411 citations · Full text

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

Brian I. Rini, Arnulf Stenzl, Romauld Zdrojowy et al. · The Lancet Oncology · 2016 · 211 citations

Sunitinib Versus Sunitinib, Urology, Genitourinary Cancer +8